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Introduction
Angiosarcoma after breast cancer conservative treatment is extremely rare pathology and its early diagnostic is complicated. 
Due to rarity of this patology, there is still no standard approach for treatment. The aim of this article is to present a clinical 
case of radiation-associated angiosarcoma (RAAS) after breast cancer conservative treatment and review the latest literature 
sources.
Case report
This case report presents 66-year-old white postmenopausal women diagnosed with left breast cancer stage I (pT1cN0M0). 
Breast preserving operation was performed and patient received adjuvant radiotherapy (50 Gy). After 5 years of the follow-
up, RAAS of the irradiated left breast was diagnosed. The clinical features of this rare occurrence of RAAS are presented and 
possible treatment options are discussed. Treatment of patient was performed in National Cancer Institute.
Conclussions
Early diagnostic, multidisciplinary approach, aggressive R0 surgical treatment and additional doses of radiotherapy – allows 
us to more successfully treat this rare pathological state. Scientific trials to delineate proper indications for RAAS treatment 
of the breast are needed.
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Įžanga
Straipsnio tikslas – aprašyti retą klinikinį su spinduliniu gydymu susijusį angiosarkomos atvejį po krūties tausojančios opera-
cijos ir spindulinio vėžio gydymo, taip pat apžvelgti naujausius literatūros šaltinius.
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Klinikinis atvejis
Straipsnyje aprašomas klinikinis 66 metų moters atvejis. Jai buvo diagnozuotas kairės krūties I stadijos vėžys (pT1cN0M0). 
2011 metais atlikta krūtį tausojanti operacija ir taikytas pooperacinės radioterapijos kursas (50 Gy). 2016 metais, po 5 metų 
nuo pirminio kairės krūties vėžio sudėtinio gydymo, šioje krūtyje nustatyta su spinduliniu gydymu susijusi angiosarkoma. 
Mes aptariame šios retos angiosarkomos klinikinį atvejį ir galimus gydymo metodus. Ligonė buvo gydoma Nacionaliniame 
vėžio institute.
Išvados
Ankstyva diagnostika, daugiadalykis aptarimas, agresyvus R0 chirurginis gydymas ir adjuvantinio spindulinio gydymo dozės 
leidžia sėkmingiau gydyti šia retą patologinę būklę. Reikalingi papildomi moksliniai tyrimai, kurie padėtų nustatyti su spindu-
liniu gydymu susijusios angiosarkomos gydymo indikacijas.
Reikšminiai žodžiai: angiosarkoma, krūties vėžys, su spinduliniu gydymu susijusi angiosarkoma
Er – positive 8/8 according Allred, Pr – positive 6/8 ac-
cording Allred, Her2 1+ negative, R0 resection. Lymph 
nodes were uninvolved pathologically. Patient received 
adjuvant radiotherapy (50 Gy) and hormotherapy 
(tamoxifen 20 mg per day). Follow-up. Annual breast 
digital mammograms and ultrasound were normal. On 
May 20th 2016 the patient visited NCI out-patient 
clinic with a complaints of a rapidly growing new masses 
in the operated and irradiated left breast. Breast physi-
cal exam: the breast was enlarged with erythematous 
infiltrated area, painless 12 cm × 5 cm and various size 
multiple cutaneous lesions; pink or red discoloration 
of the skin. Right breast – without palpable pathologic 
masses. Axillary and regional lymph nodes – without 
pathologic changes (Fig. 1).
The radiologic examination of this patient included: 
breast ultrasonography, digital mammography. 
Introduction
Angiosarcoma (AS) of breast is a very aggressive malig-
nant tumor of the vascular endothelium [1]. Overall, 
less than 1% of all soft tissue sarcomas are angiosar-
comas and primary AS of the breast represents only 
1 in 1700–2000 primary breast cancers [4]. Primary 
AS developes in patiens who have never had any his-
tory or treatment of breast cancer, and may occur in 
younger women, usually in the 20 to 40 years range. 
Secondary radiation-associated angiosarcoma (RAAS) 
developes in a woman who underwent irradiaton for 
conservative treatment of a primary breast cancer. A 
secondary angiosarcoma of the breast is associated with 
two presumed aetiologic factors: chronic lymphedema 
after a mastectomy with lymph node dissection (Stew-
art–Treves syndrome) and radiotherapy. The average 
time between radiation therapy and AS development is 
6 years, although several reports indicate this may occur 
as early as 1–2 years or as late as 41 years after treatment 
[1]. Because of RAAS rarity and difculties in radiologic 
and clinical simptoms, the early diagnosis of RAAS is 
complicated, and the overall survival and local recur-
rence results are poor. 
Case report
This case report presents 66-years-old white postmeno-
pausal women diagnosed and treated breast cancer 
pT1cN0M0 stage in National Cancer Institute, Vil-
nius, Lithuania. On 4th of June 2011 breast preserving 
operation (quadrantectomy, ipsilateral axillary lymph 
node dissection) was performed. Pathologic examina-
tion revealed invasive ductal carcinoma grade 2 (G2), 
Figure 1. Left breast with various size multiples cutaneous 
lesions; pink or red discoloration of the skin 
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Digital mammography revealed postoperative chang-
es in the left breast Bi-Rads-II, ACR I. No pathological 
changes as compared with previous mammograms. 
Breast ultrasonography revealed no pathological chang-
es, axillary and regional lymph nodes were not enlarged. 
Core biopsy of palpated tumor – possible angiosarcoma 
due to radiation therapy. 
Multidisciplinary team recommended operation, 
starting with simple mastectomy, in case of invasion 
to pectoralis major muscle – radical mastectomy by 
Halsted.
In June 2016 simple mastectomy, removing widely 
breast, irradiated and indurated tissues (28 cm × 
15 cm × 3 cm) was performed. Post-operative period 
without complications. 
Final pathological examination revealed breast an-
giosarcoma low grade G1 (associated with local radio-
therapy) R0. Final diagnosis: Carcinoma of the right 
breast pT1cN0M0 stage I (2011). Angiosarcoma of the 
right breast G1 (2016). 
Multidisciplinary team recommended to discuss ad-
juvant doses of radiotherapy.
Discussion
The risk of a second cancer malignancy among persons 
who have had a cancer previously is increasing. Imple-
menting the use of conservation therapy for breast can-
cer patients, number of reports on RAAS had increased. 
However, the small difference in the risk of subsequent 
sarcoma for breast cancer patients receiving radiothera-
py does not supersede the benefit of radiotherapy after 
breast preserving surgery [1, 4, 6]. 
The reported median latency period between ra-
diation and diagnosis of radiation-associated sarcomas 
RAAS is 6–7  years. Although several reports indicate 
this may occur as early as 1–2 years or as late as 41 years 
after treatment [2, 3, 5]. 
Retrospective analysis of 332 163 Finnish cancer pa-
tients showed the cumulative incidence of AS at 15 years 
post diagnosis – 0.9 per 1,000 for cases receiving radia-
tion (SE=0.2) and 0.1 per 1,000 for cases not receiving 
radiation (SE<0.1). 5 year results of the overal survival 
of RAAS were poor 27–35% [2]. Depla AL er al. in a 
systematic review of 74 articles analyzed data of RAAS 
222 patients. In these patients, the 5-year overal survival 
was 43%. Surgery with radiotherapy had a better 5-year 
local recurrence-free interval LRFI of 57% compared to 
34% for surgery alone (p=0.008). [4]. 
In our case report we presented and summarized very 
reare pathological condition – RAAS after 5 years of 
combined primary breast cancer treatment.
Generally, the prognosis for angiosarcoma of the 
breast is rather poor. But in our case for low grade G1 
angiosarcoma, after performed wide agressive surgery 
(R0) and additional radiotherapy – the results are more 
optimistic.
Figure 2. Left breast digital mammograhy 
Figure 3. Local control, surgery versus surgery + radiotherapy 
[4]
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Conclusions
1.  In any patients with discoloration that does not 
disappear – punch or core biopsy should be per-
formed.
2.  Surgery R0 is considered to be the treatment of 
choice, but the outcome is poor because of high 
local recurrence rates. 
3.  The achievement of R0 margins is probably of ma-
jor importance for improving the patient outcome. 
4.  Adjuvant radiotherapy doses probably decrease the 
risk of local recurrence.
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